Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of GSK3228836 Multiple Doses in Chronic Hepatitis B Subjects
CTR20210124Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bepirovirsen in Chronic Hepatitis B (CHB), sponsored by GSK. Started Feb 2021; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20210124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210124.